Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniele Laszlo

Showing results (11-20 of 41) with videos related to

Pageof 5
Sort By:
Seminars in Oncology|December 3, 2024
Gender-based differences in the efficacy of anti-EGFR/BRAF/MEK targeted therapy in patients with BRAF-mutated metastatic colorectal cancerLaura Pala, Tommaso De Pas, Emilia Cocorocchio, et al.
Ecancermedicalscience|November 7, 2014
Primary cardiac lymphoma with isolated parenchymal central nervous system relapse: report of two cases and review of the literatureJuan Montoro, Lucia Mattia, Paola Bertazzoni, et al.
Hematological Oncology|July 23, 2014
Chlorambucil-rituximab as first-line therapy in patients affected by follicular non-Hodgkin's lymphoma: a retrospective single-centre studyGiovanni Martinelli, Juan Montoro, Anna Vanazzi, et al.
European Journal of Haematology|April 20, 2004
Tailored therapy of adult acute leukaemia in Jehovah's Witnesses: unjustified reluctance to treatDaniele Laszlo, Alberto Agazzi, Aron Goldhirsch, et al.
British Journal of Haematology|October 9, 2003
Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin's lymphomaGiovanni Martinelli, Daniele Laszlo, Francesco Bertolini, et al.
International Journal of Cancer|August 12, 2004
Cyclin D3 immunoreactivity in follicular lymphoma is independent of the t(6;14)(p21.1;q32.3) translocation or cyclin D3 gene amplification and is correlated with histologic grade and Ki-67 labeling indexGiancarlo Pruneri, Stefano Valentini, Sonia Fabris, et al.
Current Oncology (Toronto, Ont.)|March 28, 2023
Exon-18-EGFR Mutated Transformed Small-Cell Lung Cancer: A Case Report and Literature ReviewNunzio Digiacomo, Tommaso De Pas, Giovanna Rossi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 26, 2005
Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapyGiovanni Martinelli, Daniele Laszlo, Andrés J M Ferreri, et al.
Seminars in Oncology|December 8, 2023
Immune-checkpoint inhibitors in anal squamous cell carcinoma: a systematic review and meta-analysisLaura Pala, Tommaso De Pas, Erika Stucchi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2010
Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter studyDaniele Laszlo, Giovanna Andreola, Luigi Rigacci, et al.
Pageof 5

Showing results (11-20 of 41) with videos related to

Sort By:
Pageof 5
Seminars in Oncology|December 3, 2024
Gender-based differences in the efficacy of anti-EGFR/BRAF/MEK targeted therapy in patients with BRAF-mutated metastatic colorectal cancerLaura Pala, Tommaso De Pas, Emilia Cocorocchio, et al.
Ecancermedicalscience|November 7, 2014
Primary cardiac lymphoma with isolated parenchymal central nervous system relapse: report of two cases and review of the literatureJuan Montoro, Lucia Mattia, Paola Bertazzoni, et al.
Hematological Oncology|July 23, 2014
Chlorambucil-rituximab as first-line therapy in patients affected by follicular non-Hodgkin's lymphoma: a retrospective single-centre studyGiovanni Martinelli, Juan Montoro, Anna Vanazzi, et al.
European Journal of Haematology|April 20, 2004
Tailored therapy of adult acute leukaemia in Jehovah's Witnesses: unjustified reluctance to treatDaniele Laszlo, Alberto Agazzi, Aron Goldhirsch, et al.
British Journal of Haematology|October 9, 2003
Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin's lymphomaGiovanni Martinelli, Daniele Laszlo, Francesco Bertolini, et al.
International Journal of Cancer|August 12, 2004
Cyclin D3 immunoreactivity in follicular lymphoma is independent of the t(6;14)(p21.1;q32.3) translocation or cyclin D3 gene amplification and is correlated with histologic grade and Ki-67 labeling indexGiancarlo Pruneri, Stefano Valentini, Sonia Fabris, et al.
Current Oncology (Toronto, Ont.)|March 28, 2023
Exon-18-EGFR Mutated Transformed Small-Cell Lung Cancer: A Case Report and Literature ReviewNunzio Digiacomo, Tommaso De Pas, Giovanna Rossi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 26, 2005
Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapyGiovanni Martinelli, Daniele Laszlo, Andrés J M Ferreri, et al.
Seminars in Oncology|December 8, 2023
Immune-checkpoint inhibitors in anal squamous cell carcinoma: a systematic review and meta-analysisLaura Pala, Tommaso De Pas, Erika Stucchi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2010
Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter studyDaniele Laszlo, Giovanna Andreola, Luigi Rigacci, et al.
Pageof 5